Everence Capital Management’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-13,420
Closed -$155K 814
2025
Q2
$155K Buy
+13,420
New +$159K 0.01% 770
2024
Q3
Sell
-42,210
Closed -$667K 766
2024
Q2
$667K Hold
42,210
0.05% 306
2024
Q1
$721K Hold
42,210
0.05% 296
2023
Q4
$745K Hold
42,210
0.05% 283
2023
Q3
$1.01M Sell
42,210
-9,650
-19% -$237K 0.08% 210
2023
Q2
$1.13M Hold
51,860
0.09% 187
2023
Q1
$1.14M Hold
51,860
0.09% 188
2022
Q4
$1.05M Sell
51,860
-10,580
-17% -$205K 0.09% 191
2022
Q3
$842K Buy
62,440
+14,450
+30% +$244K 0.08% 223
2022
Q2
$951K Buy
47,990
+7,610
+19% +$202K 0.08% 193
2022
Q1
$1.28M Sell
40,380
-10,600
-21% -$297K 0.1% 172
2021
Q4
$1.14M Buy
50,980
+11,310
+29% +$295K 0.08% 201
2021
Q3
$1.1M Buy
39,670
+180
+0.5% +$5.48K 0.09% 185
2021
Q2
$1.54M Hold
39,490
0.13% 134
2021
Q1
$1.14M Sell
39,490
-12,040
-23% -$411K 0.1% 166
2020
Q4
$1.37M Buy
51,530
+12,170
+31% +$249K 0.13% 131
2020
Q3
$601K Buy
39,360
+26,640
+209% +$559K 0.07% 238
2020
Q2
$257K Buy
+12,720
New +$228K 0.03% 499

Other funds holding CLB

Everence Capital Management's CLB Position: Q3 2025 in Review

Everence Capital Management sold out of Core Laboratories (CLB) in Q3 2025, closing a stake of 13,420 shares — an estimated $155K sold.

Everence Capital Management first reported a position in CLB in Q2 2020 and held it in 18 quarters. The position peaked at $1.54M in Q2 2021. 190 funds tracked by Wall St. Rank hold CLB as of Q3 2025.

  • Everence Capital Management reported no remaining Core Laboratories position as of Q3 2025 after selling out during the quarter.
  • Everence Capital Management sold 13,420 Core Laboratories shares in Q3 2025, an estimated $155K.
  • Everence Capital Management first reported a position in Core Laboratories in Q2 2020 and held it in 18 quarters.
  • Everence Capital Management's Core Laboratories position peaked at $1.54M in Q2 2021.
  • 190 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2025.

Based on Everence Capital Management's 13F filing for Q3 2025, filed 1 Oct 2025.